Generics Bulletin Editor’s Picks For Q1 2022
Highlights Across The Off-Patent Sector From January To March 2022
Looking back over the first quarter of 2022, Generics Bulletin executive editor David Wallace picks out highlights from January to March that include a number of major deals in the biosimilars sector, warnings of increasing price pressure on generics, and key strategy updates from companies across the off-patent sector.
